Humacyte Global, Inc
CAGE Code: 47PM8
NCAGE Code: 47PM8
Status: Active
Type: Manufacturer
Dun & Bradstreet (DUNS): 557190449
Summary
Humacyte Global, Inc is an Active Manufacturer with the Cage Code 47PM8 and is tracked by Dun & Bradstreet under DUNS Number 557190449..
Address
2525 E Nc Highway 54
Durham NC 27713-2201
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Bell Contracting Services Llc Hospital Education Greenleaf Intl Trading Inc Micro Medium Inc Ortho Lab Inc Creative Integration Technologies Reyes Clemencia Globe Communications Inc American Enterprises Nekton Technologies, Inc Duke University Medical Center Southern Technology Council Viper Express Trucking, Llc Omnisec Corp Shloke Hospitality, Llc Catsoft Hooker System Engineering Inc Eve Bio, Llc Organon Teknika Chico Produce, Inc.
Frequently Asked Questions (FAQ) for CAGE 47PM8
- What is CAGE Code 47PM8?
- 47PM8 is the unique identifier used by NATO Organizations to reference the physical entity known as Humacyte Global, Inc located at 2525 E Nc Highway 54, Durham NC 27713-2201, United States.
- Who is CAGE Code 47PM8?
- 47PM8 refers to Humacyte Global, Inc located at 2525 E Nc Highway 54, Durham NC 27713-2201, United States.
- Where is CAGE Code 47PM8 Located?
- CAGE Code 47PM8 is located in Durham, NC, USA.
Contracting History for CAGE 47PM8 Most Recent 25 Records
- W81XWH17C0200
- Modification To Add Hrpo Approval And Replace Clinical Site. Determine Safety And Efficacy Of A Novel, Bioengineered Blood Vessel - The Humacyl Vessels - For Treating Vascular Trauma In A Civilian Population Of 40 Patients.
- 14 May 2018
- Modification To Add Hrpo Approval And Replace Clinical Site. Determine Safety And Efficacy Of A Novel, Bioengineered Blood Vessel - The Humacyl Vessels - For Treating Vascular Trauma In A Civilian Population Of 40 Patients.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $3,463,048.00
- Department Of Defense (Dod)
- W81XWH17C0200
- Phase 2 Clinical Trial For Novel Bioengineered Blood Vessel (Humacyl) For Treating Vascular Trauma
- 2 Aug 2019
- Phase 2 Clinical Trial For Novel Bioengineered Blood Vessel (Humacyl) For Treating Vascular Trauma
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $4,025,472.00
- Department Of Defense (Dod)
- W81XWH17C0200
- Igf::Ot::Igf Phase 2 Clinical Trial
- 25 Sep 2017
- Igf::Ot::Igf Phase 2 Clinical Trial
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $4,025,472.00
- Department Of Defense (Dod)